Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Trading Update

1 Nov 2017 07:00

RNS Number : 1716V
Biome Technologies PLC
01 November 2017
 

 

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 ("MAR")

 

1 November 2017

 

Biome Technologies plc

 

("Biome", "the Company" or "the Group")

 

 

Biome Technologies plc, a leading bioplastics and radio frequency technology business, today publishes a trading update for the nine months ended 30 September 2017.

 

Total Group revenues achieved in Q3 were £1.5m (2016: £0.9m). This takes Group revenues for the nine months to 30 September 2017 to £4.5m, a 46% increase compared to the same period last year (2016: £3.1m) and close to the full year 2016 level of £4.6m.

 

The Group made a small profit before interest, tax, depreciation, amortisation, and share option charges for Q3 2017, making this the fourth consecutive quarter of EBITDA profitability (based on unaudited management accounts).

 

The Group's cash position as at 30 September 2017 was £2.4m (30 June 2017: £1.9m), reflecting trading activity and receipt of deposits within the Stanelco RF division.

 

 

Bioplastics Division

Revenues in the Bioplastics division in Q3 were £0.5m (Q3 2016: £0.4m), resulting in revenues in the first nine months of the financial year being £1.7m (2016: £0.9m). The revenues for the year to date have already exceeded the 2016 full year revenues of £1.6m.

 

This growth in revenue is a result of continued demand for the commercialised outer packaging, lid material and non-woven filter mesh for the US coffee pod market.

 

 

Stanelco RF Technologies Division

Revenues in the RF Technologies division in Q3 were £1.1m (Q3 2016: £0.7m), resulting in revenues in the first nine months of the financial year being £2.8m (2016: £2.2m). Good revenue levels were supported by the build and delivery of several fibre optic furnaces.

 

The order book and enquiry pipeline have continued to build with a particular focus on demand from Asia. This gives confidence for a strong outlook for this division for the remainder of the year and into the middle of 2018.

 

 

Outlook

The Group has continued its progress in the first half of the year into Q3 and the Board expects this momentum to continue for the remainder of the year.

 

- Ends -

 

 

 

For further information please contact: Biome Technologies plc

 

Paul Mines, Chief Executive Officer

Declan Brown, Group Finance Director

www.biometechnologiesplc.com

Tel: +44 (0) 2380 867 100

 

Allenby Capital

David Hart (Nominated Adviser)

Chris Crawford/Kelly Gardiner (Broker)

www.allenbycapital.com

Tel: +44 (0) 20 3328 5656

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTOKDDNOBDDKKN
Date   Source Headline
15th May 20067:01 amRNSAppointment of Adviser
3rd May 20061:05 pmRNSNotifiable Interest
2nd May 20064:58 pmRNSResult of AGM
2nd May 20062:00 pmRNSAGM Statement
10th Apr 20063:12 pmRNSAnnual Report and Accounts
7th Apr 20062:46 pmRNSAdditional Listing
13th Mar 20067:02 amRNSDirectorate Change
28th Feb 20067:02 amRNSPreliminary Results
24th Feb 20067:02 amRNSCooperation with Wal-Mart
14th Feb 20069:07 amRNSAdditional Listing
14th Feb 20067:00 amRNSUS FDA approval for Starpol
9th Feb 200610:42 amRNSIsraCaps new licence terms
9th Feb 20067:02 amRNSRe: BioProgress plc
16th Dec 20057:01 amRNSFunding for R&D facility
16th Dec 20057:01 amRNSPre Close Update
14th Dec 20057:01 amRNSLandmark deal with Perseco
8th Dec 200510:25 amRNSShare Listing Application
30th Nov 20055:40 pmRNSDirectorate Change
28th Nov 20059:24 amRNSBoard Changes
8th Nov 20057:01 amRNSPatent sale process update
3rd Nov 20054:47 pmRNSExercise of Options
1st Nov 20057:02 amRNSChange of Adviser
12th Oct 20057:00 amRNSApproval of Starpol
3rd Oct 20057:00 amRNSPatent Disposal & Update
22nd Sep 20057:02 amRNSRe Agreement
12th Sep 20057:03 amRNSDevelopment of capsule
5th Sep 20057:03 amRNSRe: Completion
30th Aug 20053:30 pmRNSDoc re. Result of EGM
30th Aug 200511:08 amRNSEGM Statement
30th Aug 20057:03 amRNSRe Agreement
5th Aug 200511:15 amRNSRe posting of circular
1st Aug 20057:01 amRNSDirector Appointment
28th Jul 20057:01 amRNSUpdate re: trials with ASDA
26th Jul 20057:00 amRNSContract Win
19th Jul 20057:00 amRNSRe Agreement
5th Jul 20057:01 amRNSRe Joint Venture
29th Jun 20057:00 amRNSInterim Results
22nd Jun 20057:00 amRNSUpdate re trials with Asda
8th Jun 20055:29 pmRNSAdditional Listing
8th Jun 200510:00 amRNSAppointment of Group MD
8th Jun 20057:50 amRNSPlacing of Ordinary Shares
6th Jun 20057:01 amRNSAcquisition
3rd Jun 20053:02 pmRNSIssue of Equity
23rd May 20057:01 amRNSRe Contract
17th May 200512:12 pmRNSAdditional Listing
10th May 20057:00 amRNSUpdate re. trials with Asda
29th Apr 20053:46 pmRNSHolding(s) in Company
25th Apr 20053:27 pmRNSDirector Shareholding
22nd Apr 20052:24 pmRNSResult of AGM
22nd Apr 200511:31 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.